Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT07412756

ClinicalTrials.gov

Trial ID
T-ctgov-NCT07412756
Registry
ClinicalTrials.gov
NCT number
NCT07412756
CTIS number
2025-522308-25-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly and Company
Phase
PHASE3
Indication
Depressive Disorder, Major
Status
RECRUITING
Start date
2026-02-09
Primary completion
2028-02
Registered countries
Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
Sites
179

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-08-31

Notes on the record

Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting NCT07412756 in their own text.